TVRD · Tvardi Therapeutics, Inc.
AI read · Neutral
The AI's read
The early human study showed the drug reached its intended target and was better tolerated. Animal studies also found benefits in colitis, but they do not show that patients will improve. Tvardi says it needs more funding and regulatory clearance before starting the ulcerative colitis study. Its liver cancer results are still expected in early 2027, so this update offers promise but no new patient outcome.